Clinical Trial

Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH

Study acronym: MIRROR-PAH
Recruiting
View on ClinicalTrials.gov →
Summary
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.
Trial Details
NCT Number NCT07667673
Lead Sponsor Istanbul University - Cerrahpasa
Conditions Pulmonary Hypertension, Pulmonary Arterial Hypertension, Right Ventricular Function
Enrollment 50 participants
Start Date 2026-05-11
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-25